ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX): Valuation After Upgraded Guidance and Strong Third Quarter Revenue
Telix Pharmaceuticals (ASX:TLX) has raised its 2025 revenue forecast to $800 million to $820 million after reporting third quarter revenue of $206 million, a significant increase from last year’s $135 million.
See our latest analysis for Telix Pharmaceuticals.
Telix’s share price has pulled back sharply over the last three months, but momentum has begun to build again as strong Q3 revenue and upgraded guidance have improved sentiment. Despite a one-year total shareholder return of -34.6%,...